Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
VivoSim Labs's 5-Year RORE % for the quarter that ended in Dec. 2025 was -26.13%.
The industry rank for VivoSim Labs's 5-Year RORE % or its related term are showing as below:
FRA:4OR's 5-Year RORE % is ranked worse than 71.97% of 1138
companies
in the Biotechnology industry
Industry Median: -10.67
vs FRA:4OR: -26.13
VivoSim Labs (FRA:4OR) 5-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
VivoSim Labs 5-Year RORE % Related Terms
VivoSim Labs 5-Year RORE % Historical Data
* Premium members only.
The historical data trend for VivoSim Labs's 5-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4OR vs SLXN, CDT, CLDI: 5-Year RORE % Comparison
For the Biotechnology subindustry, VivoSim Labs's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VivoSim Labs 5-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VivoSim Labs's 5-Year RORE % distribution charts can be found below:
* The bar in red indicates where VivoSim Labs's 5-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 5-year before.
VivoSim Labs (FRA:4OR) has a 5-Year RORE % of -26.13 as of Dec. 2025. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on VivoSim Labs and its competitors. According to the industry distribution chart, VivoSim Labs ranks #819 out of 1138 companies in the Biotechnology industry, placing it in the top 72%.
Is VivoSim Labs' 5-Year RORE % too high?
VivoSim Labs' current 5-Year RORE % is -26.13. Based on the distribution chart, VivoSim Labs ranks #819 out of 1138 companies in the Biotechnology industry, which is below the industry midpoint. Overall, VivoSim Labs has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' 5-Year RORE % compare to SLXN and CDT?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #819 out of 1138 companies for 5-Year RORE %. This places VivoSim Labs in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Biotechnology company?
A good 5-Year RORE % depends on the Biotechnology industry context. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on VivoSim Labs and its competitors. VivoSim Labs's current 5-Year RORE % is -26.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current 5-Year RORE % of -26.13. The stock's GF Value™ is €8.71, compared to a current price of €3.49 — trading 59.9% below its estimated fair value. The current 5-Year RORE % is -26.13. VivoSim Labs' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current 5-Year RORE % is -26.13 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 59.9% below its estimated GF Value™ of €8.71.
Key valuation signals for FRA:4OR:
5-Year RORE %: -26.13
GF Value™: €8.71 vs. price of €3.49 (59.9% below fair value)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
39GF Score
Get the complete analysis for FRA:4OR
5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 
